Cheraghlou et al1 reviewed data from the National Cancer Database (NCDB) to evaluate whether overall survival differs when patients with T1a-T2a melanomas are treated with Mohs micrographic surgery (MMS) in high- vs low-volume or academic vs nonacademic facilities. Analysis was limited to this population based on previous work, which reported improved overall survival among patients with T1a-T2a melanoma treated with MMS compared with wide local excision (WLE).2 The authors present 10 years of retrospective NCDB data on 4062 T1a-T2a melanomas treated with MMS and report that patients were nearly 30% less likely to die when MMS was performed at academic vs nonacademic facilities (hazard ratio [HR], 0.730; 95% CI, 0.596-0.895; P = .002) and 20% less likely to die when MMS was performed at high- vs low-volume facilities (HR, 0.795; 95% CI, 0.648-0.977; P = .03).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Miller CJ, Bichakjian CK. Mohs Micrographic Surgery for Melanoma—Do Outcomes Vary Among Treatment Facilities? JAMA Dermatol. Published online March 31, 2021. doi:10.1001/jamadermatol.2021.0022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: